Sign in

    Noah Eisenberg

    Research Analyst at JPMorgan Chase & Co.

    Noah Eisenberg is an Executive Director and Equity Research Analyst at JPMorgan Chase & Co., specializing in the coverage of the Real Estate Investment Trusts (REITs) sector with a particular focus on lodging and leisure companies. He provides in-depth research and recommendations on companies such as Marriott International, Hilton Worldwide Holdings, Host Hotels & Resorts, and Pebblebrook Hotel Trust, and his analysis has been recognized for its accuracy and insight, reflected in a strong track record and positive reviews on industry platforms. Eisenberg began his career in equity research at Bank of America Merrill Lynch before joining JPMorgan in 2018, where he steadily advanced to his current role. He holds FINRA Series 7, 63, and 86/87 licenses, underscoring his expertise and professional standing within the investment research community.

    Noah Eisenberg's questions to IGM Biosciences (IGMS) leadership

    Noah Eisenberg's questions to IGM Biosciences (IGMS) leadership • Q4 2022

    Question

    Noah Eisenberg of JPMorgan Chase & Co. asked about the potential for synergistic combinations of IGM-8444 with EGFR or KRAS inhibitors, given the trial's stratification by KRAS status.

    Answer

    Chief Medical Officer Dr. Chris Takimoto and Chief Scientific Officer Dr. Bruce Keyt responded that they expect IGM-8444 to be active across various molecular subtypes, including KRAS mutant and wild-type. While the current strategy is to develop the drug broadly, they are open to exploring combinations with agents like EGFR inhibitors in the future and are currently investigating these possibilities pre-clinically.

    Ask Fintool Equity Research AI